[1]
Amer KM, Thomson JE, Congiusta D, Dobitsch A, Chaudhry A, Li M, Chaudhry A, Bozzo A, Siracuse B, Aytekin MN, Ghert M, Beebe KS. Epidemiology, Incidence, and Survival of Rhabdomyosarcoma Subtypes: SEER and ICES Database Analysis. Journal of orthopaedic research : official publication of the Orthopaedic Research Society. 2019 Oct:37(10):2226-2230. doi: 10.1002/jor.24387. Epub 2019 Jun 28
[PubMed PMID: 31161653]
[2]
Li H, Sisoudiya SD, Martin-Giacalone BA, Khayat MM, Dugan-Perez S, Marquez-Do DA, Scheurer ME, Muzny D, Boerwinkle E, Gibbs RA, Chi YY, Barkauskas DA, Lo T, Hall D, Stewart DR, Schiffman JD, Skapek SX, Hawkins DS, Plon SE, Sabo A, Lupo PJ. Germline Cancer Predisposition Variants in Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group. Journal of the National Cancer Institute. 2021 Jul 1:113(7):875-883. doi: 10.1093/jnci/djaa204. Epub
[PubMed PMID: 33372952]
[3]
Bisogno G, Hawkins DS. An unresolved issue in rhabdomyosarcoma treatment: The duration of chemotherapy. Pediatric blood & cancer. 2020 May:67(5):e28174. doi: 10.1002/pbc.28174. Epub 2020 Jan 28
[PubMed PMID: 31994316]
[4]
Skapek SX, Ferrari A, Gupta AA, Lupo PJ, Butler E, Shipley J, Barr FG, Hawkins DS. Rhabdomyosarcoma. Nature reviews. Disease primers. 2019 Jan 7:5(1):1. doi: 10.1038/s41572-018-0051-2. Epub 2019 Jan 7
[PubMed PMID: 30617281]
[5]
Chen C, Dorado Garcia H, Scheer M, Henssen AG. Current and Future Treatment Strategies for Rhabdomyosarcoma. Frontiers in oncology. 2019:9():1458. doi: 10.3389/fonc.2019.01458. Epub 2019 Dec 20
[PubMed PMID: 31921698]
[6]
Zhang J, Walsh MF, Wu G, Edmonson MN, Gruber TA, Easton J, Hedges D, Ma X, Zhou X, Yergeau DA, Wilkinson MR, Vadodaria B, Chen X, McGee RB, Hines-Dowell S, Nuccio R, Quinn E, Shurtleff SA, Rusch M, Patel A, Becksfort JB, Wang S, Weaver MS, Ding L, Mardis ER, Wilson RK, Gajjar A, Ellison DW, Pappo AS, Pui CH, Nichols KE, Downing JR. Germline Mutations in Predisposition Genes in Pediatric Cancer. The New England journal of medicine. 2015 Dec 10:373(24):2336-2346. doi: 10.1056/NEJMoa1508054. Epub 2015 Nov 18
[PubMed PMID: 26580448]
[7]
Arndt CA. Risk stratification of rhabdomyosarcoma: a moving target. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2013:():415-9
[PubMed PMID: 23714563]
[8]
Yamada S, Harada Y, Noguchi H, Satoh N, Kimura S, Nakayama T, Tanimoto A. Embryonal rhabdomyosarcoma arising from the uterine corpus in a postmenopausal female: a surgical case challenging the genuine diagnosis on a cytology specimen. Diagnostic pathology. 2016 Jan 12:11():3. doi: 10.1186/s13000-016-0451-0. Epub 2016 Jan 12
[PubMed PMID: 26755204]
Level 3 (low-level) evidence
[9]
Sardinha MGP, Ramajo FM, Ponce CC, Marques CF, Bittencourt CMF, Caldano FG, Moço JMFL, Yano OL, Reis PMDR, Malaguti VS, de Sousa CTRG, Nogueira RC. Uterine cavity embryonal rhabdomyosarcoma. Autopsy & case reports. 2019 Jul-Sep:9(3):e2019104. doi: 10.4322/acr.2019.104. Epub 2019 Jul 12
[PubMed PMID: 31372362]
Level 3 (low-level) evidence
[10]
Agaram NP. Evolving classification of rhabdomyosarcoma. Histopathology. 2022 Jan:80(1):98-108. doi: 10.1111/his.14449. Epub
[PubMed PMID: 34958505]
[11]
Parham DM, Barr FG. Classification of rhabdomyosarcoma and its molecular basis. Advances in anatomic pathology. 2013 Nov:20(6):387-97. doi: 10.1097/PAP.0b013e3182a92d0d. Epub
[PubMed PMID: 24113309]
Level 3 (low-level) evidence
[12]
Lav R, Heera R, Cherian LM. Decoding the 'embryonic' nature of embryonal rhabdomyosarcoma. Journal of developmental origins of health and disease. 2015 Jun:6(3):163-8. doi: 10.1017/S204017441500015X. Epub 2015 Mar 5
[PubMed PMID: 25740270]
[13]
Kashi VP, Hatley ME, Galindo RL. Probing for a deeper understanding of rhabdomyosarcoma: insights from complementary model systems. Nature reviews. Cancer. 2015 Jul:15(7):426-39. doi: 10.1038/nrc3961. Epub
[PubMed PMID: 26105539]
Level 3 (low-level) evidence
[14]
DeGeorge KC, Holt HR, Hodges SC. Bladder Cancer: Diagnosis and Treatment. American family physician. 2017 Oct 15:96(8):507-514
[PubMed PMID: 29094888]
[15]
Dagher R, Helman L. Rhabdomyosarcoma: an overview. The oncologist. 1999:4(1):34-44
[PubMed PMID: 10337369]
Level 3 (low-level) evidence
[16]
van Ewijk R, Schoot RA, Sparber-Sauer M, Ter Horst SAJ, Jehanno N, Borgwardt L, de Keizer B, Merks JHM, de Luca A, McHugh K, von Kalle T, Schäfer JF, van Rijn RR, Cooperative Weichteilsarkom Studiengruppe Imaging Group, the European Society of Paediatric Radiology Oncology Task Force and the European Paediatric Soft Tissue Sarcoma Study Group Imaging Committee. European guideline for imaging in paediatric and adolescent rhabdomyosarcoma - joint statement by the European Paediatric Soft Tissue Sarcoma Study Group, the Cooperative Weichteilsarkom Studiengruppe and the Oncology Task Force of the European Society of Paediatric Radiology. Pediatric radiology. 2021 Sep:51(10):1940-1951. doi: 10.1007/s00247-021-05081-0. Epub 2021 Jun 17
[PubMed PMID: 34137936]
[17]
Murphey MD, Kransdorf MJ. Staging and Classification of Primary Musculoskeletal Bone and Soft-Tissue Tumors According to the 2020 WHO Update, From the AJR Special Series on Cancer Staging. AJR. American journal of roentgenology. 2021 Nov:217(5):1038-1052. doi: 10.2214/AJR.21.25658. Epub 2021 Apr 14
[PubMed PMID: 33852362]
[18]
de Vries ISA, van Ewijk R, Adriaansen LME, Bohte AE, Braat AJAT, Fajardo RD, Hiemcke-Jiwa LS, Hol MLF, Ter Horst SAJ, de Keizer B, Knops RRG, Meister MT, Schoot RA, Smeele LE, van Scheltinga ST, Vaarwerk B, Merks JHM, van Rijn RR. Imaging in rhabdomyosarcoma: a patient journey. Pediatric radiology. 2023 Apr:53(4):788-812. doi: 10.1007/s00247-023-05596-8. Epub 2023 Feb 27
[PubMed PMID: 36843091]
[19]
Fetzko S, Fonseca A, Frances Wedekind M, Gupta AA, Setty BA, Schraw J, Lupo PJ, Guillerman RP, Butala AA, Russell H, Nicholls L, Walterhouse D, Hawkins DS, Okcu MF. Is Detection of Relapse by Surveillance Imaging Associated With Longer Survival in Patients With Rhabdomyosarcoma? Journal of pediatric hematology/oncology. 2022 Aug 1:44(6):305-312. doi: 10.1097/MPH.0000000000002429. Epub 2022 Feb 9
[PubMed PMID: 35137727]
[20]
Yechieli RL, Mandeville HC, Hiniker SM, Bernier-Chastagner V, McGovern S, Scarzello G, Wolden S, Cameron A, Breneman J, Fajardo RD, Donaldson SS. Rhabdomyosarcoma. Pediatric blood & cancer. 2021 May:68 Suppl 2():e28254. doi: 10.1002/pbc.28254. Epub
[PubMed PMID: 33818882]
[21]
Maurer HM, Beltangady M, Gehan EA, Crist W, Hammond D, Hays DM, Heyn R, Lawrence W, Newton W, Ortega J. The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer. 1988 Jan 15:61(2):209-20
[PubMed PMID: 3275486]
[22]
Crane JN, Xue W, Qumseya A, Gao Z, Arndt CAS, Donaldson SS, Harrison DJ, Hawkins DS, Linardic CM, Mascarenhas L, Meyer WH, Rodeberg DA, Rudzinski ER, Shulkin BL, Walterhouse DO, Venkatramani R, Weiss AR. Clinical group and modified TNM stage for rhabdomyosarcoma: A review from the Children's Oncology Group. Pediatric blood & cancer. 2022 Jun:69(6):e29644. doi: 10.1002/pbc.29644. Epub 2022 Mar 6
[PubMed PMID: 35253352]
[23]
Casey DL, Mandeville H, Bradley JA, Ter Horst SAJ, Sheyn A, Timmermann B, Wolden SL. Local control of parameningeal rhabdomyosarcoma: An expert consensus guideline from the International Soft Tissue Sarcoma Consortium (INSTRuCT). Pediatric blood & cancer. 2022 Jul:69(7):e29751. doi: 10.1002/pbc.29751. Epub 2022 Apr 29
[PubMed PMID: 35484997]
Level 3 (low-level) evidence
[24]
Elsebaie MAT, Amgad M, Elkashash A, Elgebaly AS, Ashal GGEL, Shash E, Elsayed Z. Management of Low and Intermediate Risk Adult Rhabdomyosarcoma: A Pooled Survival Analysis of 553 Patients. Scientific reports. 2018 Jun 19:8(1):9337. doi: 10.1038/s41598-018-27556-1. Epub 2018 Jun 19
[PubMed PMID: 29921891]
[25]
Nishida Y, Kawai A. Surgical treatment for extremity rhabdomyosarcoma: longitudinal national questionnaire survey in Japan. Japanese journal of clinical oncology. 2022 Apr 6:52(4):362-369. doi: 10.1093/jjco/hyab206. Epub
[PubMed PMID: 34963137]
Level 3 (low-level) evidence
[26]
Rogers TN, Seitz G, Fuchs J, Martelli H, Dasgupta R, Routh JC, Hawkins DS, Koscielniak E, Bisogno G, Rodeberg DA. Surgical management of paratesticular rhabdomyosarcoma: A consensus opinion from the Children's Oncology Group, European paediatric Soft tissue sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe. Pediatric blood & cancer. 2021 Apr:68(4):e28938. doi: 10.1002/pbc.28938. Epub 2021 Feb 1
[PubMed PMID: 33522706]
Level 3 (low-level) evidence
[27]
Fernandez-Pineda I, Spunt SL, Parida L, Krasin MJ, Davidoff AM, Rao BN. Vaginal tumors in childhood: the experience of St. Jude Children's Research Hospital. Journal of pediatric surgery. 2011 Nov:46(11):2071-5. doi: 10.1016/j.jpedsurg.2011.05.003. Epub
[PubMed PMID: 22075335]
[28]
Filipas D, Fisch M, Stein R, Gutjahr P, Hohenfellner R, Thüroff JW. Rhabdomyosarcoma of the bladder, prostate or vagina: the role of surgery. BJU international. 2004 Jan:93(1):125-9
[PubMed PMID: 14678383]
[29]
Ellerkamp V, Schmidt A, Warmann SW, Eckert F, Schaefer J, Paulsen F, Fuchs J. Detailed functional results after bladder-preserving surgery and high-dose-rate brachytherapy in pediatric bladder/prostate rhabdomyosarcoma. Journal of cancer research and clinical oncology. 2023 Jul:149(7):3161-3170. doi: 10.1007/s00432-022-04209-5. Epub 2022 Jul 25
[PubMed PMID: 35879432]
[30]
Rodeberg DA, Wharam MD, Lyden ER, Stoner JA, Brown K, Wolden SL, Paidas CN, Donaldson SS, Hawkins DS, Spunt SL, Arndt CA. Delayed primary excision with subsequent modification of radiotherapy dose for intermediate-risk rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee. International journal of cancer. 2015 Jul 1:137(1):204-11. doi: 10.1002/ijc.29351. Epub 2014 Dec 10
[PubMed PMID: 25418440]
[31]
Lautz TB, Chi YY, Li M, Wolden SL, Casey DL, Routh JC, Granberg CF, Binite O, Rudzinski ER, Hawkins DS, Venkatramani R, Rodeberg DA. Benefit of delayed primary excision in rhabdomyosarcoma: A report from the Children's Oncology Group. Cancer. 2021 Jan 15:127(2):275-283. doi: 10.1002/cncr.33275. Epub 2020 Oct 20
[PubMed PMID: 33079399]
Level 3 (low-level) evidence
[32]
Miwa S, Yamamoto N, Hayashi K, Takeuchi A, Igarashi K, Tsuchiya H. Recent Advances and Challenges in the Treatment of Rhabdomyosarcoma. Cancers. 2020 Jul 2:12(7):. doi: 10.3390/cancers12071758. Epub 2020 Jul 2
[PubMed PMID: 32630642]
Level 3 (low-level) evidence
[33]
Choi Y,Lim DH, The impact of radiotherapy on clinical outcomes in parameningeal rhabdomyosarcoma. Radiation oncology journal. 2016 Dec
[PubMed PMID: 27609110]
Level 2 (mid-level) evidence
[34]
Hogeboom CJ, Grosser SC, Guthrie KA, Thomas PR, D'Angio GJ, Breslow NE. Stature loss following treatment for Wilms tumor. Medical and pediatric oncology. 2001 Feb:36(2):295-304
[PubMed PMID: 11452938]
[35]
Paulino AC. Late effects of radiotherapy for pediatric extremity sarcomas. International journal of radiation oncology, biology, physics. 2004 Sep 1:60(1):265-74
[PubMed PMID: 15337565]
[36]
Hessels AC, Langendijk JA, Gawryszuk A, Heersters MAAM, van der Salm NLM, Tissing WJE, van der Weide HL, Maduro JH. Review - Late toxicity of abdominal and pelvic radiotherapy for childhood cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2022 May:170():27-36. doi: 10.1016/j.radonc.2022.02.029. Epub 2022 Mar 4
[PubMed PMID: 35257849]
[37]
Lockney NA, Friedman DN, Wexler LH, Sklar CA, Casey DL, Wolden SL. Late Toxicities of Intensity-Modulated Radiation Therapy for Head and Neck Rhabdomyosarcoma. Pediatric blood & cancer. 2016 Sep:63(9):1608-14. doi: 10.1002/pbc.26061. Epub 2016 May 16
[PubMed PMID: 27195454]
Level 3 (low-level) evidence
[38]
Arndt CA, Stoner JA, Hawkins DS, Rodeberg DA, Hayes-Jordan AA, Paidas CN, Parham DM, Teot LA, Wharam MD, Breneman JC, Donaldson SS, Anderson JR, Meyer WH. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Nov 1:27(31):5182-8. doi: 10.1200/JCO.2009.22.3768. Epub 2009 Sep 21
[PubMed PMID: 19770373]
[39]
Pappo AS, Anderson JR, Crist WM, Wharam MD, Breitfeld PP, Hawkins D, Raney RB, Womer RB, Parham DM, Qualman SJ, Grier HE. Survival after relapse in children and adolescents with rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1999 Nov:17(11):3487-93
[PubMed PMID: 10550146]
[40]
Mazzoleni S, Bisogno G, Garaventa A, Cecchetto G, Ferrari A, Sotti G, Donfrancesco A, Madon E, Casula L, Carli M, Associazione Italiana di Ematologia e Oncologia Pediatrica Soft Tissue Sarcoma Committee. Outcomes and prognostic factors after recurrence in children and adolescents with nonmetastatic rhabdomyosarcoma. Cancer. 2005 Jul 1:104(1):183-90
[PubMed PMID: 15895378]
[41]
Cohen RJ, Curtis RE, Inskip PD, Fraumeni JF Jr. The risk of developing second cancers among survivors of childhood soft tissue sarcoma. Cancer. 2005 Jun 1:103(11):2391-6
[PubMed PMID: 15852362]
[42]
Heyn R, Khan F, Ensign LG, Donaldson SS, Ruymann F, Smith MA, Vietti T, Maurer HM. Acute myeloid leukemia in patients treated for rhabdomyosarcoma with cyclophosphamide and low-dose etoposide on Intergroup Rhabdomyosarcoma Study III: an interim report. Medical and pediatric oncology. 1994:23(2):99-106
[PubMed PMID: 8202048]
[43]
Korkmaz A, Topal T, Oter S. Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP activation. Cell biology and toxicology. 2007 Sep:23(5):303-12
[PubMed PMID: 17225077]
[44]
Andriole GL, Sandlund JT, Miser JS, Arasi V, Linehan M, Magrath IT. The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1987 May:5(5):799-803
[PubMed PMID: 3106585]
[45]
Shepherd JD, Pringle LE, Barnett MJ, Klingemann HG, Reece DE, Phillips GL. Mesna versus hyperhydration for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplantation. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1991 Nov:9(11):2016-20
[PubMed PMID: 1941060]
[46]
Watson AR,Rance CP,Bain J, Long term effects of cyclophosphamide on testicular function. British medical journal (Clinical research ed.). 1985 Nov 23;
[PubMed PMID: 3933709]
[47]
Kenney LB, Laufer MR, Grant FD, Grier H, Diller L. High risk of infertility and long term gonadal damage in males treated with high dose cyclophosphamide for sarcoma during childhood. Cancer. 2001 Feb 1:91(3):613-21
[PubMed PMID: 11169946]
[48]
Koyama H, Wada T, Nishizawa Y, Iwanaga T, Aoki Y. Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer. 1977 Apr:39(4):1403-9
[PubMed PMID: 851940]
[49]
van de Velde ME, Kaspers GL, Abbink FCH, Wilhelm AJ, Ket JCF, van den Berg MH. Vincristine-induced peripheral neuropathy in children with cancer: A systematic review. Critical reviews in oncology/hematology. 2017 Jun:114():114-130. doi: 10.1016/j.critrevonc.2017.04.004. Epub 2017 Apr 6
[PubMed PMID: 28477739]
Level 1 (high-level) evidence
[50]
Wang X, Feng J, Li Z, Zhang X, Chen J, Feng G. Characteristics and prognosis of embryonal rhabdomyosarcoma in children and adolescents: An analysis of 464 cases from the SEER database. Pediatric investigation. 2020 Dec:4(4):242-249. doi: 10.1002/ped4.12220. Epub 2020 Dec 28
[PubMed PMID: 33376951]
Level 3 (low-level) evidence
[51]
Oberlin O, Rey A, Lyden E, Bisogno G, Stevens MC, Meyer WH, Carli M, Anderson JR. Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 May 10:26(14):2384-9. doi: 10.1200/JCO.2007.14.7207. Epub
[PubMed PMID: 18467730]